Patient Pre Screener
Language Preference:

Participation in clinical trials depends on several factors, including (but not limited to) your age, your other medical conditions, current medication intake, and willingness to participate.

Patients who use the online pre-screener will be matched to a clinical trial and will find out which trial locations are closest geographically. If no clinical trials currently match your specific medical conditions or if a local site is not currently enrolling, you may sign up to be alerted when a clinical trial match is available. All information is strictly confidential and is never rented or sold.

Clinical Trials

The Gemini Trials: NCT04410978 & NCT04410991

  • Relapsing Multiple Sclerosis (RMS)
  • ages 18 to 55 years

The Gemini 1 and Gemini 2 Trials are Phase III clinical trials designed to assess the efficacy and safety of the trial drug against an existing treatment medication, teriflunomide. The efficacy and safety of the trial drug is measured by comparing the number of relapses per year confirmed by an independent group of MS specialists in patients diagnosed with relapsing forms of multiple sclerosis (RMS). Patients will be randomly selected to receive the trial drug or the existing treatment medication.

Additional goals of the trials will be to test the effect of the trial drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the trial medication.

Find Out More About the Gemini Trials.

The Hercules Trial: NCT04411641

  • Secondary Progressive MS, Non-Relapsing (nrSPMS)
  • ages 18 to 60 years

The Hercules Trial is a Phase III clinical trial designed to test how well the trial drug works and whether it is safe. The trial drug will be compared to placebo (a tablet that looks the same as the trial drug but has no therapeutic effect). The main effect that is being tested is whether the trial drug delays disability progression in patients diagnosed with non-relapsing secondary progressive multiple sclerosis (nrSPMS). Patients will be randomly selected to receive the trial drug or placebo. Patients are twice as likely to receive the trial drug vs placebo. The trial drug is being compared to placebo because approved treatments specifically for non-relapsing SPMS (nrSPMS) are not available in all countries or covered by insurance in all patients.

Additional goals of the trial will be to test the effect of the trial drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the trial medication.

Find out more about the Hercules Trial.

The Perseus Trial: NCT04458051

  • Primary Progressive Multiple Sclerosis (PPMS)
  • ages 18 to 55 years

The Perseus Trial is a Phase III clinical trial designed to test how well the trial drug works and whether it is safe. The trial drug will be compared to placebo (a tablet that looks the same as the trial drug but has no therapeutic effect). The main effect that is being tested is whether the trial drug delays disease progression in patients diagnosed with primary progressive multiple sclerosis (PPMS). Patients will be randomly selected to receive the trial drug or placebo. Patients are twice as likely to receive the trial drug vs placebo. The trial drug is being compared to placebo because approved treatments for PPMS are not available in all countries or covered by insurance in all patients.

Additional goals of the trial will be to test the effect of the trial drug on disability progression, magnetic resonance imaging (MRI) lesions, the ability to learn and process information, and quality of life, as well as the safety and tolerability of the trial medication.

Find Out More About the Perseus Trial.

Wait… Can We Stay In Touch?

MyMStrials.com would like to stay in-touch.

No SPAM, we don’t sell or rent your information. Fully private.

No Thanks